1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Clinical experience of reoperative right ventricular outflow tract reconstruction with valved conduits: risk factors for conduit failure in long-term follow-up

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Reconstruction of right ventricular outflow tract in patients with congenital heart disease in various age groups remains a controversial issue. Currently, a little is known about the fate of secondary and subsequent conduit. The aim of the study was to determine risk factors of conduit failure, evaluate long-term conduit survival, find out which type of conduit should be preferred in case of reoperations. We performed a retrospective analysis of a total of 249 records of valved conduit secondary and subsequent replacement in right ventricular outflow tract in 197 patients. Median follow-up was 5.7 years. The study endpoints were defined as conduit explants; balloon dilatation of the graft (excluding balloon dilatation of left/right pulmonary artery), transcatheter pulmonary valve implantation; heart transplantation or death of the patient. There were total of 21 deaths (11% mortality) among 197 patients during the follow-up, 2 patients underwent heart transplant, in 23 implanted conduits pulmonary angioplasty or/including transcatheter pulmonary valve implantation was afterwards performed due to graft failure, conduit had to be explanted in 46 cases. After 28 years follow-up, freedom from graft failure after 5 years was 77%, 48% after 10 years and 21% after 15 years. Reoperative right ventricular outflow tract reconstruction demonstrates good mid-term and acceptable long-term outcomes regardless of the type of conduit implanted. Worse long-term graft survival of secondary and further conduits is associated with younger age of the recipient at implantation, small size of the conduit, younger age of donor and male donor in case of allograft implantation.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          More powerful procedures for multiple significance testing

          The problem of multiple comparisons is discussed in the context of medical research. The need for more powerful procedures than classical multiple comparison procedures is indicated. To this end some new, general and simple procedures are discussed and demonstrated by two examples from the medical literature: the neuropsychologic effects of unidentified childhood exposure to lead, and the sleep patterns of sober chronic alcoholics.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Factors affecting longevity of homograft valves used in right ventricular outflow tract reconstruction for congenital heart disease.

            Few studies have explored the long-term function of cryopreserved homograft valves used for reconstruction of the right ventricular tract (RVOT) in patients with congenital heart disease. Among 205 patients receiving cryopreserved homografts for reconstruction of the RVOT between November 1985 and April 1999, the outcome of 220 homografts in 183 operative survivors was analyzed. There were 150 pulmonary and 70 aortic homografts used. Median age at implantation was 4.4 years (mean 6.9+/-7.6 years, range 3 days to 48 years). End points included (1) patient survival, (2) homograft failure (valve explant or late death), and (3) homograft dysfunction (homograft insufficiency or homograft stenosis). Survival was 88% at 10 years. Freedom from homograft failure was 74+/-4% at 5 years and 54+/-7% at 10 years. Univariable analysis identified younger age, longer donor warm ischemic time, valve Z: value <2, and previous procedure as risk factors for homograft failure and dysfunction. Aortic homograft type and extracardiac operative technique predicted homograft failure but not dysfunction. For patients
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Right ventricular outflow tract reconstruction with a polytetrafluoroethylene monocusp valve: a twelve-year experience.

              Transannular patching of the right ventricular outflow tract results in pulmonary insufficiency. Biologic monocusp valves prevent early pulmonary insufficiency but usually become nonfunctional in less than 1 year. Polytetrafluoroethylene monocusp leaflets demonstrated favorable characteristics in our animal studies and have been applied to a variety of right ventricular outflow tract reconstructions at our institution. From 1994 through 2006, 192 patients (mean age, 3.3 +/- 5.0 years) underwent right ventricular outflow tract reconstruction with a polytetrafluoroethylene monocusp valve (192 patients; 202 implants). Intraoperative, early postoperative, and late follow-up echocardiographic data (mean interval, 4.9 +/- 3.1 years; range, 6 months to 12 years) were retrospectively obtained to compare clinical outcomes among three preoperative diagnostic groups: patients undergoing initial repair of tetralogy of Fallot or pulmonary atresia/ventricular septal defect (group I), patients undergoing redo right ventricular outflow tract procedures (group II), and patients undergoing complex initial repairs (group III). There were 4 early and 5 late deaths (9/192; 5%). The difference between the preoperative and postoperative peak right ventricular outflow tract gradients was significant (71.2 vs 23.1; P < .0001). Twenty-five (14%) patients had mild-to-moderate right ventricular outflow tract stenosis at one or more locations proximal and/or distal to the monocusp patch (mean gradient, 44.7 +/- 20.3 mm Hg). Freedom from increased pulmonary insufficiency greater than moderate was 86% at 1 year, 68% at 5 years, and 48% at 10 years. Twenty-five patients have undergone 35 reoperations 4.2 +/- 3.1 years (range, 3 months to 10 years after initial repair). Kaplan-Meier freedom from reoperation was 96%, 89%, and 82% at 1, 5, and 10 years. Freedom from reoperation in group II (69%) was significantly different from group I (88%; P = .01) and from group III (90%; P = .02), but there was no difference between groups I and III. Use of a polytetrafluoroethylene monocusp valve prevents early and significantly reduces midterm pulmonary insufficiency. It is relatively inexpensive, easy to construct, and remains free from significant stenosis in the majority of patients. We have not witnessed significant calcification or pulmonary embolization, and the only antithrombic agent used has been low-dose aspirin.
                Bookmark

                Author and article information

                Contributors
                mariiahavova@gmail.com
                Journal
                Cell Tissue Bank
                Cell Tissue Bank
                Cell and Tissue Banking
                Springer Netherlands (Dordrecht )
                1389-9333
                1573-6814
                21 April 2023
                21 April 2023
                2024
                : 25
                : 1
                : 87-98
                Affiliations
                [1 ]Department of Cardiovascular Surgery, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, ( https://ror.org/024d6js02) V Uvalu 84, 15006 Prague 5, Czech Republic
                [2 ]Children’s Heart Centre, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, ( https://ror.org/024d6js02) Prague, Czech Republic
                [3 ]GRID grid.412826.b, ISNI 0000 0004 0611 0905, Department of Transplantation and Tissue Bank, , National Allograft Heart Valve Bank, Motol University Hospital, ; Prague, Czech Republic
                [4 ]Department of Bioinformatics, 2nd Faculty of Medicine, Charles University, ( https://ror.org/024d6js02) Prague, Czech Republic
                [5 ]Clinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine, ( https://ror.org/036zr1b90) Videnska 1958/9, 140 21 Prague 4, Czech Republic
                [6 ]Department of Pathology and Molecular Medicine, 3rd Faculty of Medicine, Charles University and Thomayer Hospital, ( https://ror.org/024d6js02) Videnska 800, 140 59 Prague 4, Czech Republic
                Author information
                http://orcid.org/0000-0001-5100-4325
                https://orcid.org/0000-0003-3272-7928
                https://orcid.org/0000-0003-4307-6155
                https://orcid.org/0000-0001-9566-0527
                https://orcid.org/0000-0002-7927-5597
                https://orcid.org/0000-0001-7493-2140
                Article
                10088
                10.1007/s10561-023-10088-y
                10902091
                37085639
                022e2ae4-1ea3-41ff-94d9-d23e8ce024a4
                © The Author(s) 2023

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 2 July 2022
                : 1 April 2023
                Funding
                Funded by: Charles University
                Categories
                Full Length Paper
                Custom metadata
                © Springer Nature B.V. 2024

                Molecular medicine
                right ventricular outflow tract,reoperation,allograft,valved conduit,xenograft,conduit failure

                Comments

                Comment on this article